纳米技术介导的药物治疗肥胖症及其相关合并症。,Advanced Healthcare Materials

当前位置： X-MOL 学术 › Adv. Healthcare Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

纳米技术介导的药物治疗肥胖症及其相关合并症。
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2019-04-02 , DOI: 10.1002/adhm.201801184
Yung-Hao Tsou ₁ , Bin Wang ₂ , William Ho ₁ , Bin Hu ₂ , Pei Tang ₂ , Sydney Sweet ₁ , Xue-Qing Zhang ₂ , Xiaoyang Xu ₁

Affiliation

肥胖是严重的健康问题，在全球范围内影响着人类。肥胖症的发生率被美国医学会确认为慢性疾病，并且继续以加速的速度增长，肥胖症已成为对人类健康的主要威胁之一。体重增加过多与代谢综合征有关，代谢综合征被证明会增加患心脏病和2型糖尿病等慢性疾病的风险，使本已负担沉重的医疗系统负担沉重，并增加了全世界的死亡率。减肥手术和药物治疗等可用的治疗方法通常伴随着不良副作用和患者依从性差。纳米技术是一种新兴的技术，具有广泛的生物医学应用，为改善包括肥胖症在内的许多疾病的治疗提供了前所未有的机会。这篇综述介绍了肥胖和肥胖相关的合并症。重点介绍并讨论了基于纳米技术的药物输送策略的最新发展。另外，讨论了开发具有翻译潜力的纳米制剂的挑战和考虑。这篇综述的总体目标是加深对用于治疗肥胖症和相关合并症的纳米药物的设计和开发的了解。

"点击查看英文标题和摘要"

Nanotechnology-Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities.

Obesity is a serious health issue affecting humanity on a global scale. Recognized by the American Medical Association as a chronic disease, the incidence of obesity continues to grow at an accelerating rate and obesity has become one of the major threats to human health. Excessive weight gain is tied to metabolic syndrome, which is shown to increase the risk of chronic diseases, such as heart disease and type 2 diabetes, taxing an already overburdened healthcare system and increasing mortality worldwide. Available treatments such as bariatric surgery and pharmacotherapy are often accompanied by adverse side effects and poor patient compliance. Nanotechnology, an emerging technology with a wide range of biomedical applications, has provided an unprecedented opportunity to improve the treatment of many diseases, including obesity. This review provides an introduction to obesity and obesity‐related comorbidities. The most recent developments of nanotechnology‐based drug delivery strategies are highlighted and discussed. Additionally, challenges and consideration for the development of nanoformulations with translational potential are discussed. The overall objective of this review is to enhance the understanding of the design and development of nanomedicine for treatments of obesity and related comorbidities.

更新日期：2019-04-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南